Home›The Library›Tesamorelin
Tesamorelin
Tesamorelin is not a grey-market story — it's an approved prescription medicine (Egrifta, 2010) backed by real, large, peer-reviewed Phase 3 trials. But the approval is narrow: reducing excess abdominal fat in HIV patients with lipodystrophy, nothing broader. It has no approval and no trial evidence for the general anti-aging or fat-loss use it's increasingly marketed for outside that population.
On this page
In brief
Should you care? Yes — this is the one GHRH analog on this site that actually cleared FDA approval, which makes it a useful yardstick for how far short sermorelin, CJC-1295 and hexarelin fall.The short version
- FDA-approved (Egrifta, 10 November 2010) for excess abdominal fat in HIV-associated lipodystrophy — a narrow, specific indication.
- Real Phase 3 trial evidence backs the approval: a measured reduction in visceral fat versus placebo.
- Not approved, and untested, for the general anti-aging or fat-loss use it's marketed for outside that population.
What it is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), developed by Theratechnologies, that stimulates the pituitary to release the body's own growth hormone. FDA approved it as Egrifta on 10 November 2010 specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — the first, and still only, approved treatment for that condition. It has since been reformulated (Egrifta SV, then Egrifta WR).
The trial evidence
The pivotal trial (Falutz et al., N Engl J Med 2007;357(23):2359-70, PMID 18057338) randomized HIV patients with excess abdominal fat to tesamorelin or placebo over 26 weeks and found a 15.2% reduction in visceral adipose tissue versus a 5.0% increase on placebo, with improvements in triglycerides and cholesterol ratio. A pooled analysis of two Phase 3 trials with safety-extension data (Falutz et al., J Clin Endocrinol Metab 2010;95(9):4291-4304, PMID 20554713) confirmed the effect and characterized longer-term safety.
Why it's not an anti-aging drug
Egrifta's FDA label states plainly that it is not indicated for weight-loss management generally, is not approved for HIV-negative patients, and is not approved for any anti-aging use — despite being marketed off-label in exactly that space by longevity clinics trading on its "real GHRH" credibility. It's contraindicated in disrupted pituitary-hypothalamic function and carries warnings about increased IGF-1 and glucose intolerance.
A real approval doesn't transfer to a different population
The trial evidence behind tesamorelin is genuinely strong — for HIV-associated lipodystrophy specifically. Buying it for general fat loss or anti-aging means buying outside the population the evidence was ever generated in.
Where it sits against this site's other GHRH pages
Sermorelin, CJC-1295 and hexarelin are all either discontinued or have never been approved as medicines. Tesamorelin is the one member of this drug class that went all the way through Phase 3 and got approved — for one specific condition. That's the whole story: real trial evidence exists, it just doesn't extend nearly as far as its off-label marketing implies.
References
- Falutz et al., "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV," N Engl J Med 2007;357(23):2359-70, PMID 18057338.
- Falutz et al., "Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients with Excess Abdominal Fat: a Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials," J Clin Endocrinol Metab 2010;95(9):4291-4304, PMID 20554713.
- FDA approval of Egrifta (tesamorelin), 10 November 2010 (accessdata.fda.gov, NDA 022505).